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Prodigious efforts and landmark discoveries have led toward significant advances in our under-
standing of atherosclerosis. Despite significant efforts, atherosclerosis continues globally to be a
leading cause of mortality and reduced quality of life. With surges in the prevalence of obesity and
diabetes, atherosclerosis is expected to have an even more pronounced impact upon the global
burden of disease. It is imperative to develop strategies for the early detection of disease. Positron
emission tomography (PET) imaging utilizing [18F]fluorodeoxyglucose (FDG) may provide a non-
invasive means of characterizing inflammatory activity within atherosclerotic plaque, thus serving
as a surrogate biomarker for detecting vulnerable plaque. The aim of this review is to explore the
rationale for performing FDG imaging, provide an overview into the mechanism of action, and
summarize findings from the early application of FDG PET imaging in the clinical setting to
evaluate vascular disease. Alternative imaging biomarkers and approaches are briefly discussed.
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Vessels in the elderly restrict the transit of blood
through thickening of the tunics.
Leonardo da Vinci, 1452–1519.
INTRODUCTION
Leonardo da Vinci presented perhaps one of the first
known descriptions of atherosclerosis. In his collection
of notes from post-mortem observations of human
anatomy and poorly understood pathology, da Vinci
merged what were the distinct disciplines of art and
science to describe and depict human development and
physiology.1 Five-hundred years later, significant
advances in technology enable non-invasive visualiza-
tion of atherosclerosis using multiple imaging
modalities, moving beyond anatomical characterization
toward directly imaging disease processes and patho-
physiology. The current challenge for imaging scientists
lies in identifying high-risk atherosclerotic lesions that
could lead to coronary or cerebrovascular sequelae prior
to adverse vascular events such as myocardial infarction
and stroke, and thereby enable personalized therapy
while mitigating risk.
Herein, we present a general introduction to
advanced non-invasive imaging of atherosclerosis with
particular emphasis upon [18F]fluorodeoxyglucose
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(FDG) positron emission tomography (PET). We will
discuss the role of FDG PET for the identification of the
high-risk ‘‘vulnerable plaque’’ across the arterial tree
and its potential for monitoring disease progression and
response to therapy.
Atherosclerosis
Atherosclerosis is the most common underlying
pathology responsible for adverse cardiovascular out-
comes including angina, myocardial infarction, transient
ischemic attacks, and stroke. With an aging population,
obesity and diabetes pandemics, cardiovascular disease
is projected to become a leading source of global disease
burden.2-5
Atherosclerosis is a chronic disease process that
begins with the disruption and inflammation of vascular
endothelium, leading to the formation of lipid-rich fatty
streaks that may arise as early as infancy. 6 Inflamma-
tory activity within these lesions increases as lipids and
macrophages progressively accumulate, resulting in
complex remodeling of fibrofatty plaques.7,8 A typical
plaque consists of a central lipid-rich core bound by a
fibrous cap. The fibrous cap can suddenly rupture or
erode away, exposing the core of the plaque to clotting
factors within blood. Activation of these factors results
in a cascade that can completely occlude the vessel and
induce severe ischemic injury or tissue necrosis.9,10
Plaque that is thrombosis-prone and likely to
progress rapidly, resulting in vessel occlusion is referred
to as vulnerable plaque.11 Proposed major criteria for
defining vulnerable plaque include the presence of
active inflammation, particularly increased activated
macrophage content.11 Evidence suggests that the
impending risk to a patient posed by the presence of
vulnerable plaque cannot be sufficiently determined by
assessing for the anatomic presence of plaque at a
specific site or vessel within the arterial tree. Rather,
global plaque burden across the entire arterial bed may
be a stronger correlate to determine patient risk, thus
allowing for risk stratification.12 In this regard, non-
invasive cardiovascular imaging may be useful as it
could visualize disease across the entire arterial bed, and
may also be utilized to monitor disease progression or
even regression with novel therapies.
Non-invasive Imaging of Atherosclerosis
Contrast-Enhanced Ultrasound Contrast-
enhanced ultrasound takes advantage of portability,
bedside imaging and wide availability of carotid ultra-
sound. Injection of intravascular micro-bubbles permits
the visualization of micro- and macro-vasculature, but
more importantly, intraplaque neovascularization.13
Neovascularization occurs during the early stages of
atherosclerosis where undeveloped leaky micro-vessels
are formed within the plaque.14 The risk associated with
these micro-vessels is the development of an intraplaque
hemorrhage that potentiates inflammation and contributes
toward plaque instability.14,15 Therefore, neovasculariza-
tion detected by contrast-enhanced ultrasound may serve
as a marker of a high-risk lesion or a vulnerable plaque.16
Furthermore, the intima-media is hypoechoic while the
adventitia is echogenic, resulting in contrast that can
delineate vessel lumen and plaque ulcerations or
irregularities on the plaque surface.17,18 Additionally,
intima-media thickness (IMT) can also be measured by
contrast-enhanced ultrasound and is a marker of pre-
mature atherosclerosis.
3-DIMENSIONAL ULTRASOUND
3D ultrasound imaging builds further upon the prin-
ciples of ultrasound imaging. With 3D ultrasound, it is
feasible to visualize carotid plaque and accurately quantify
plaque and vessel volume. Plaque volume assessed with
3D ultrasound is a more robust parameter than IMT and
thus a highly sensitive means to detect plaque progression,
as much as two orders of magnitude better than IMT.19-22
Plaque grows and extends longitudinally at a faster rate
than it thickens. Using 3D ultrasound it is possible to
utilize significantly reduced sample sizes to evaluate the
impact of an intervention upon plaque progression.21
Whether 3D ultrasound can define other high-risk plaque
parameters such as ulceration and other aspects of plaque
morphology is being evaluated in collaboration with the
Canadian Atherosclerosis Imaging Network (clinicaltri-
als.gov NCT01456403).23,24
COMPUTED TOMOGRAPHY (CT)
Computed tomography (CT) enables accurate iden-
tification of stenosis within arterial vessels with a high
degree of special resolution.25 In addition, CT offers the
unique ability to characterize calcification within pla-
que26 and stage lesions according to their developmental
phase to determine the risk of plaque rupture.27 A non-
calcified lipid-rich plaque reflects plaque in the early
stages of atherosclerosis.28 With remodeling, a non-
calcified lesion transitions into a mixed plaque that
contains calcium deposits and a lipid-rich core.28 Pro-
gressive accumulation of calcium deposits within plaque
leads to the formation of a dense mature calcified
plaque. Mixed and non-calcified plaques are at greatest
risk for plaque erosion or rupture.29 Indeed the presence
of spotty calcification in lesions evaluated with multi-
slice computed tomography has been associated with
acute coronary syndrome.30
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MAGNETIC RESONANCE IMAGING (MRI)
Magnetic resonance imaging (MRI) offers good
spatial resolution for the delineation of vascular lumen
and offers advantages in demonstrating plaque structure
and composition.31 MRI can accurately assess mean
wall thickness and vessel wall area.32 In addition, MRI
can lend insight into plaque composition including the
lipid-rich core, intraplaque hemorrhage and fibrous
cap.33-35 Compared to CT, MRI does not use ionizing
radiation. For these reasons, MRI has been utilized as an
endpoint in clinical trials to monitor disease progression
and the impact of therapy.36 Novel contrast agents that
may enable targeted MRI-based molecular imaging of
plaque progression are under currently evaluation.37-41
POSITRON EMISSION TOMOGRAPHY (PET)
PET imaging utilizes radiolabeled ligands and
tracers that may directly bind to specific targeted
molecules or accumulate within specific tissue beds,
thereby providing insight into active biologic metabolic
processes.42 This is an important advantage as it is
feasible to probe directly the in vivo expression of
molecular and metabolic activity within plaque. In
comparison to the anatomic imaging modalities that
mainly characterize plaque structure, composition and
morphology, PET can evaluate dynamic intraplaque
activity such as inflammation, active plaque calcifica-
tion, and other biologic processes (Figure 1).
HYBRID PET IMAGING
The spatial resolution of clinical PET imaging
ranges between 3 and 5 mm.43 With such resolution, it is
challenging to assess the uptake of radiotracer in small
structures such as the carotid and coronary vasculature.
To circumvent this limitation, hybrid imaging is per-
formed where PET images are co-registered with either
CT or more recently MRI44,45 (Figure 1). Thus, hybrid
Figure 1. Detection of inflamed plaque in a symptomatic patient a significantly stenotic left
internal carotid artery. In transverse and coronal contrast-enhanced CT images (top row), there is
evidence for significant obliteration of the lumen with little calcification on CT. Hybrid PET/CT
images provide evidence for increased [18F]fluorodeoxyglucose atthe site of the symptomatic
lesion (bottom row). 24 (Reproduced with permission of Informa UK, Ltd.).
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imaging may contribute toward greater sensitivity for
the anatomical detection of plaque, as well as potentially
increased specificity for active disease detection.
IMAGING WITH [18F]FDG PET
‘‘The prime cause of cancer is the replacement of
the respiration of oxygen in normal body cells by a
fermentation of sugar’’ (The Prime Cause and Preven-
tion of Cancer, Lecture by Otto Warburg, Annual
Meeting of Nobelists, Lindau, Germany, 1966). This
pivotal discovery by Nobel Laureate Dr. Otto Heinrich
Warburg in 1920s paved the way for future clinical
application of [18F]FDG imaging. By the early 1980s,
FDG was being used to distinguish between benign and
malignant lesions, define metabolic activity of cancer
cells and myocardium.46-48 Subsequently, one of the
initial applications for imaging vascular inflammation
was in the setting of Takayasu Arteritis.49 Rudd et al50
further expanded the use of FDG for evaluating athero-
sclerotic plaque within carotid vasculature and
subsequently demonstrated that this is a highly repro-
ducible technique (Figure 2).51
THE RATIONALE FOR [18F]FDG PET IMAGING OF
ATHEROSCLEROSIS
Active inflammation within plaque has been pro-
posed as a major criterion to identify high-risk
vulnerable plaque.12 Furthermore, the inflammatory
burden within ruptured plaque, as reflected by activated
macrophages, is significantly increased.52 Macrophages
potentiate localized inflammatory responses and are
pivotal mediators of atherosclerosis. Macrophages them-
selves have high metabolic rates and require an equally
abundant energy supply.53 In fact, in comparison to
smooth muscle cells, foam cells consume significantly
greater amounts of oxygen.54 This is partly due to
phagocytic activity consisting of oxidative or respiratory
bursts that yield superoxides and hydrogen peroxide to
degrade engulfed material.55
Radiolabelled FDG is a glucose analog that is taken
up by active cells to fuel in vivo metabolic processes.56
Therefore, FDG uptake may serve as a marker of
metabolic activity within a specific tissue. Importantly,
given that activated macrophages have high metabolic
rates, localized uptake of FDG within plaque may serve
as a surrogate marker of an inflamed high-risk lesion.
Indeed in patients with a history of transient ischemic
attacks arising from a specific carotid artery distribution,
as well as significantly stenosed internal carotid artery,
FDG was found to localize to macrophage-rich regions50
(Figure 3). The question that arises is whether the
observed FDG activity is actually reflective of FDG
taken up by macrophages, as opposed to surrounding
inflammatory cells.
Kubota et al57have demonstrated that FDG and
2-deoxy-D-[3H]glucose (3H-DG) uptake is greatest in
macrophage-rich regions assessed by macro- and micro-
autoradiography in an experimental tumor-induced
Figure 2. Reproducible carotid and aortic [18F]FDG uptake imaged with hybrid PET/CT over
2 weeks. A reflects carotid CT, PET, and hybrid PET/CT images demonstrating reproducible FDG
uptake in the right coronary artery (arrows). Similarly, B is indicative of reproducible FDG uptake
at the aortic arch and descending aorta of a patient (arrows) (Reprinted from Ref51with permission
from Elsevier).
1214 Cocker et al Journal of Nuclear Cardiology
What Leonardo da Vinci could not see November/December 2012
murine model. Moreover, cellular uptake studies also
demonstrate that FDG uptake is almost three-fold
greater in macrophages, as compared to tumor cells.58
These findings suggest that FDG uptake is a marker of
macrophage activity and further research reveals that
FDG may also be a marker of early foam cell
development.59
Finally, pioneering work by Rudd et al,50 Tawakol
et al,60 and others61-66 supports an association between
FDG uptake quantified in human carotid plaque speci-
mens with macrophage-specific CD68 immunohistology
staining (Figure 4).
INSIGHTS INTO ATHEROSCLEROTIC DISEASE
ACROSS VASCULAR BEDS DERIVED FROM
[18F]FDG PET
Carotid Vasculature
The relationship between carotid plaque composi-
tion and FDG uptake has been evaluated in several
studies.67 In terms of calcification, an inverse relation-
ship between calcium content within carotid plaque and
FDG uptake is noted.61 Lipid-rich necrotic plaque has
been shown to have greater FDG uptake than collage-
nous or calcified plaque.68 Additionally, FDG uptake has
also been related to high-risk morphological features of
carotid plaque such as positive remodeling, low atten-
uation profile (suggestive of a lipid-rich core), and
luminal irregularity (marker of plaque ulceration), as
characterized with hybrid PET/CT imaging,62 inferring
that FDG uptake may identify patients at higher risk of
vascular events. Indeed FDG uptake within carotid
vasculature has been related to cerebral micro-embo-
lism69 and risk of stroke.70
FDG uptake in carotid vasculature has been shown
to correlate with serum levels of C-reactive protein, a
marker of systemic inflammation.67,71 This supports the
concept of defining a ‘‘vulnerable patient’’ whereby the
presence of inflamed plaque within one node of the
arterial tree may increase the likelihood for the presence
of a vulnerable lesions within other vascular beds.71
Furthermore, other pre-existing co-morbidities may
contribute toward the burden of risk in certain patient
populations. Patients presenting with impaired glucose
tolerance and type-2 diabetes mellitus have increased
carotid FDG uptake that correlates with Framingham
Figure 3. Tritriated deoxyglucose autoradiography of an excised plaque from a symptomatic
patient establishes that silver grains accumulate between the lipid core and fibrous cap within
macrophages (inset) (magnification: 910 and 920) (Reprinted from Ref50 with permission from
Wolters Kluwer Health).
Figure 4. Mean within-patient [18F]fluorodeoxyglucose
uptake (expressed as a target-to-background ratio) is signifi-
cantly correlated with inflammation (r = 0.85; P \ .001).
Inflammation was defined as the percent of CD68 macrophage
staining with immunohistology (Reprinted from Ref60 with
permission from Elsevier).
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risk score.72 Likewise, patients presenting with meta-
bolic syndrome or with features suggestive of metabolic
syndrome also have increased carotid FDG uptake.73,74
There is also evidence that suggests that symptom-
atic carotid lesions tend to have greater FDG uptake
when compared to asymptomatic lesions, although the
extent of vascular stenosis is an important determinant.50
In general, while the degree of vascular stenosis eval-
uated with angiography is related to FDG uptake, 25%
of non-stenotic lesions detected in a vascular territory
compatible with patient presentation using high-resolu-
tion MRI angiography has significantly inflamed plaques
that can be imaged with FDG.75 Therefore, FDG
imaging of atherosclerotic lesions may be of incremental
benefit when performed in conjunction with angiogra-
phy (e.g., CTA or MRA) to identify culprit lesions at
high risk of rupture.75
Large Arterial Vasculature
Possibly, the first clinical experience of imaging
FDG uptake in large arterial vasculature was reported by
Yun et al.76 From a cohort of 156 patients referred for
various clinical indications, Yun et al77 reported that
51% of subjects had evidence for FDG uptake at the
level of the abdominal aorta, 51% at the iliac, and 63%
at proximal femoral arteries. Along all vascular beds,
age and hypercholesterolemia were correlated with the
degree of FDG uptake.77 Of further interest, a variation
existed among the atherosclerotic risk factors associated
with FDG uptake across vascular beds.77 These risk
factors included age and hypercholesterolemia (abdom-
inal aorta and iliac arteries), hypertension (iliac arteries),
and diabetes (femoral arteries).77 These findings suggest
that each atherogenic risk factor may have non-uniform
potency in contributing to disease progression in differ-
ent vascular beds. In addition to inflammation, aging has
been associated with increased aortic wall and calcifi-
cation volume, as well as metabolically active inflamed
lesions78-80 Female patients, patients with cardiovascu-
lar disease and those with cardiovascular risk factors
have also been noted to present with increased FDG
uptake or highly inflamed plaques, while diabetic
patients may have more pronounced aortic
calcification.81
Coronary Vasculature
Imaging of the coronary vasculature has proven
more challenging due to the small size of these vessels.
Confounders such as cardiac motion, myocardial FDG
uptake and the spatial resolution of PET have impeded
progress in imaging FDG uptake in coronary vessels.
Despite such challenges, Dunphy et al82 presented what
may be the first clinical experience of imaging coronary
vasculature using FDG. They evaluated calcification and
FDG uptake within the coronary arteries of 78 patients
referred for oncology imaging82 and found that there
was a significant correlation between coronary FDG
uptake and abnormal myocardial perfusion in 32
patients.82 FDG uptake was also associated with cardiac
risk factors, although no cardiac events were reported
during a follow-up period of 7 months.82 However, 34
patients were excluded from the analysis due to severe
motion artifacts. Similarly, in a larger cohort assessed by
Saam et al,83 FDG uptake at the left anterior descending
artery would only be assessed 55% of patients. None-
theless, uptake was related to hypertension, coronary
heart disease, body mass index, calcified plaque burden,
and pericardial fat volume.
In order to suppress myocardial FDG uptake,
Wykrzykowska et al84 instructed patients to consume a
low-carbohydrate, high-fat meal the night prior to
imaging and drink a vegetable oil-based drink on the
morning of the imaging study. In 32 patients with a
history of treated malignancy and who underwent both
FDG PET/CT and cardiac catherization, good cardiac
(muscle) FDG suppression was achieved in 63% of
patients.84 Coronary FDG uptake was identified in 15
patients, and when compared to angiography results,
there was a trend toward an association between
anatomic disease and metabolic FDG uptake.84 Further-
more, FDG uptake in the left main coronary artery has
been shown to be higher in patients presenting with
acute coronary syndrome when compared to those with
stable angina.85
Multi-vascular Disease
The interrelationship of atherosclerotic disease
across arterial beds has also been evaluated using FDG
imaging. Studies suggest that among different vascular
beds, there is evidence for variable FDG uptake,82,86
while there is a positive relationship between uptake in
adjacent territories and along paired left and right
arterial beds.87 Multi-vascular evaluation of disease has
been proposed, given that high levels of FDG uptake
across major vascular beds including the aorta, iliac, and
carotid arteries has been shown to be predictive of future
cardiovascular events.88
In terms of identifying patients at greatest risk, older
patients presenting with more cardiovascular risk factors
tend to have more inflamed active and calcified inactive
plaques.89 Although quantification of FDG uptake is a
highly reproducible measure, it does vary over time
suggesting that inflammation may be a transient feature
of atherosclerosis which waxes and wanes as disease
progresses.51,90-92
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THE EMERGENCE OF [18F]FDG IN CLINICAL
TRIALS
Serial FDG PET scanning has the potential to
evaluate changes in inflammatory activity. Lifestyle
modification induces a detectable reduction in FDG
uptake within aortic and iliac vasculature.93 Likewise,
reduced FDG uptake in the aorta and carotid vessels has
been observed in association with Simvastatin lipid-
lowering therapy94 (Figure 5). Furthermore, in patients
randomized to low- and high-dose Atorvastatin therapy
and followed for 6 months, high-dose therapy was
associated with significantly reduced FDG uptake at
the femoral artery and aorta.95 A similar reduction in
inflammation has also been observed following treat-
ment with Atorvastatin for 12 weeks.96
More recently, 130 patients were randomized to
either dalcetrapib (a novel HDL raising drug) or placebo
to determine whether dalcetrapib modulates plaque pro-
gression and inflammation.36 Treated patients had
reduced FDG uptake at the most diseased segments of
carotid artery.36 Upon dividing patients into three tertiles
according to total change in vessel area at 24 months,
patients in the two lowest tertiles had reduced vascular
inflammation observed after 6 months (P = .01).36 Thus,
FDG PET may be a sensitive and specific marker to non-
invasively monitor disease progression and response to
therapy. Ongoing trials such as the Canadian Atheroscle-
rosis Imaging Network (CAIN) will contribute toward
validating and establishing FDG PET against advanced
immunohistology, as well as develop other imaging-
derived biomarkers using a multimodality approach to
characterize aspects of plaque biology, disease burden,
and identifying high-risk lesions.
LIMITATIONS OF PET/CT IMAGING
Given that FDG imaging of vasculature is a
relatively new area of science and investigation, it
suffers from several limitations. Although FDG uptake
is related to macrophage expression, direct evidence
demonstrating that FDG is taken up directly into
macrophage cells is still lacking. This may be achiev-
able in the future with higher resolution imaging and
amplified immunohistology. Imaging coronary vascula-
ture with FDG continues to be hampered by myocardial
motion and myocardial FDG uptake. Acquiring respira-
tory- and cardiac-gated images may reduce the impact of
coronary vessel motion. Furthermore, as described,
patient preparation and diets may lower myocardial
FDG uptake.
Serial imaging is required to accurately stage
atherosclerosis as it matures, waxes, and wanes. PET
Figure 5. Reduced [18F]FDG following simvastatin therapy. Representative images of a patient
on dietary management alone (top row). Three-months of dietary management alone had no impact
upon FDG uptake in aortic and carotid vasculature (arrows). However, FDG uptake is visibly
reduced in the carotid arteries and aortic arch following 3 months of therapy with simvastatin
(middle row). Hybrid FDG PET/CT images demonstrate that following 3 months of therapy with
simvastatin, there is no evidence for visible FDG uptake (bottom row) (Reprinted from Ref94with
permission Elsevier).
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and CT imaging requires exposure to radiation which
currently precludes the feasibility of frequent serial
imaging. Algorithms to reduce patient radiation expo-
sure are under development and will eventually
contribute toward enabling serial imaging. Hybrid
PET/MRI and PET/CT imaging also require accurate
image co-registration between both modalities, espe-
cially when evaluating small structures such as the
internal carotid vasculature. Slight patient motion
between image acquisitions can result in misalignment
that can bias attenuation correction, precluding accurate
co-localization, and image interpretation. The use of
neck-braces and hybrid scanning systems can signifi-
cantly reduce this.
EMERGING PET/CT IMAGING PROBES FOR
HUMAN ATHEROSCLEROSIS
With the limitations of FDG and the complexity of
atherosclerotic process, other surrogate makers of inflam-
mation have also been used in human including:
[11C]PK11195, [11C]choline and 68Ga-[1,4,7,10-tetraa-
zacyclododecane-N,N0,N00,N9000-tetraacetic acid]-D-Phe1,
Tyr3-octreotate (DOTATATE) (Table 1). [11C]PK11195
is a selective ligand of a translocator protein that
is highly expressed by macrophages.97-99 Similarly,
[68Ga]DOTATATE binds to somatostatin receptors sub-
type 2 that are expressed by macrophages.100 The uptake of
[11C]PK11195 and [68Ga]DOTATATE are considered to
be indicative of macrophage density within plaque.
[11C]choline differs in that it is taken up by inflammatory
cells—primarily macrophages, following which it under-
goes phosphorylation and is metabolized into forming
phosphatidylcholine that is eventually incorporated into the
cellular membrane.101 Other tracers such as Annexin-V
that are currently being utilized to detect apoptosis may be
more specific markers of phagocytosing macrophages are
being evaluated as single-photon emission computed
tomography radiotracers but can also be labeled with
18F.102-104
In addition to inflammation, calcification of plaque
may also contribute toward potentiating plaque vulner-
ability.105-107 Hydroxyapatite is expressed in regions
with active calcium deposition. [18F]sodium fluoride
(NaF) binds to hydroxyapatite molecules by replacing
hydroxyl groups, and could, therefore, serve as a
surrogate marker of active calcification within plaque108
(Figure 6). Early findings suggest that NaF uptake
imaged with PET may identify regions of active calcium
deposition.109 Recently, NaF has been applied in coro-
nary vasculature where compared to FDG, there is very
little competing radiotracer uptake by myocardium
resulting in high target-to-background signal.109
Figure 6. NaF PET/CT imaging of left and right internal carotid arteries of active calcification in a
72-year-old symptomatic patient evaluated at the University of Ottawa Heart Institute. Upper row
evidence of NaF uptake with a small foci of calcification on CT in the left internal carotid
symptomatic culprit vessel. There is a mismatch between the region of NaF uptake and calcification
on CT. Lower row Evidence of calcium nodules with matched NaF uptake at the right internal
carotid artery.
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These tracers are still very early in development and
application. Further studies are required to establish and
validate them prior to wider application in clinical
research and potential future clinical application.
INTEGRATION OF PET/CT IMAGING
BIOMARKERS TO UNDERSTAND PLAQUE
PROGRESSION
Utilizing PET/CT imaging biomarkers, it may be
possible to non-invasively stage lesions and assess
different aspects of plaque progression. Among a cohort
of 45 oncology patients, plaque was characterized for
inflammation (FDG uptake), active mineral deposition
(NaF uptake) and calcification (CT).109 Of 105 lesions
that had NaF uptake, 81 (77.1%) had evidence of
calcification on CT, while 18 (14.5%) had evidence of
FDG uptake.109 Therefore, one could hypothesize that
imaging macrophages with FDG, active calcification
imaging with NaF and calcium deposition with com-
puted tomography could be markers of independent
processes, and that these markers could be utilized to
stage atheroma formation, disease progression and
potentially plaque and patient vulnerability.
One may speculate that in the early stages of
advanced atherosclerosis, only FDG uptake would be
detected as inflammation is predominant process present
(Figure 7). Active calcification progressively initiates
given that the inflammatory cascade contributes to
calcium deposition. As inflammation peaks, early cal-
cium deposits would also be present. From imaging, this
phase of atheroma progression would be reflected by
uptake of both FDG and NaF. Once the density of
calcium deposits exceeds a certain threshold, these
would also be visible on CT—possibly as early speckled
calcification (a presumed marker of risk on CT
Figure 7. A proposed schematic staging inflammatory and calcification activity within athero-
sclerotic lesions with FDG and NaF as imaging biomarkers. During early stages of atherosclerosis,
inflammation is the predominant mechanism active within plaque. During these stages, [18F]FDG
may be taken up by the lesion. As inflammation peaks, the risk of plaque rupture may increase.
Inflammation also contributes toward initiating calcium metabolism within lesions that results in
the formation of early calcium deposits. This would be reflected by uptake of both FDG and
hydroxyapatite-specific [18F]sodium fluoride (NaF). Once the density of calcium deposits exceeds
a certain threshold, it becomes visible with CT. During active calcification, plaque may still be
vulnerable. Eventually, the calcification and mineralization processes exceed the inflammatory
activity present within plaque, which might be demarcated by only NaF uptake (in the absence of
FDG), as well as calcium deposits on CT. Ongoing calcification eventually leads to forming an end-
stage stable atheroma that is densely calcified with only evidence for calcium on CT. Model of
plaque progression (top bar) is adapted from Koenig and Khuseyinova115.
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angiography studies).30 Eventually, calcification and
mineralization processes would exceed the inflammatory
activity present within plaque. At this stage, there would
be evidence of NaF uptake in the absence of FDG as
well as calcium deposits on CT. Ongoing calcification
may finally lead to development of an end-stage
longstanding atheroma that is densely calcified with
very little active calcium turnover. At this final stage,
there would only be evidence for calcium on CT.
CONCLUSION
Considerable advancement has occurred in imaging
atherosclerosis, with FDG PET/CT at the forefront for
characterizing actively inflamed plaque. FDG uptake
within plaque has transitioned from an incidental finding
to a potential biomarker of vulnerable plaque that has
even been implemented to evaluate the efficacy of
vascular risk reduction therapy. Despite the proliferation
of imaging research, significant progress is yet to be
achieved in fully understanding the molecular biology of
plaque progression and rupture. Recent pre-clinical
developments may help in understanding how FDG
and other novel tracers track inflammation in
plaque.42,110,111
While FDG imaging has enhanced our understand-
ing of the inflammatory processes that underlie
atherosclerosis, further studies are needed to validate
FDG uptake. It also remains to be determined whether
FDG uptake within plaque could be a specific marker of
activated, polarized M1 (pro-inflammatory) or M2 (anti-
inflammatory) macrophages,112 as validated by
advanced immunohistology. Furthermore, whether
FDG uptake is truly predictive of future cardiovascular
events and outcomes remains to be determined. Also,
while reductions in FDG uptake have been observed
following therapies that modify vascular risk, to date, a
reduction in subsequent downstream vascular events has
only been demonstrated in small observational studies.
Prospective trials will further yield insight into the role
of FDG to detect inflamed carotid plaque, as validated
by advanced immunohistochemistry in patients with
high-risk carotid artery disease36,113 and its role in
imaging other vascular beds as in the BIOIMAGE
study.114 Furthermore, although FDG has advantages in
light of its widespread availability and is currently the
PET/CT imaging biomarker of choice for large trials
evaluating plaque inflammation and progression, whe-
ther it will be the optimal PET/CT plaque imaging
biomarker remains to determined.
While we have moved far beyond da Vinci’s initial
gross observations 500 years ago to visualizing inherent
processes within plaque, we still need to bridge the gap
between translating imaging of atherosclerosis to
accurately predicting life-threatening vascular events.
At that point, we may begin to realize imaging-guided
personalized care for patients with atherosclerosis.
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